Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-02-01 22:38 | 2018-04-16 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $80.08 | 17,379 | $1,391,710 | 40,685 | -29.9% |
| 2018-04-17 22:29 | 2018-04-13 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $80.09 | 22,544 | $1,805,632 | 28,273 | -44.4% |
| 2017-12-06 01:32 | 2017-12-04 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $86.18 | 36,585 | $3,152,895 | 54,885 | -40.0% |
| 2016-12-19 22:40 | 2016-12-16 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $72.65 | 20,242 | $1,470,616 | 11,479 | -63.8% |
| 2015-07-29 20:30 | 2015-07-28 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $84.96 | 25,000 | $2,124,000 | 62,728 | -28.5% |
| 2014-07-30 23:32 | 2014-07-28 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | OPT+S | $63.30 | 2,065 | $130,715 | 7,810 | -20.9% |
| 2014-07-28 22:07 | 2014-07-25 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $63.90 | 30,000 | $1,917,000 | 52,798 | -36.2% |
| 2013-04-29 20:08 | 2013-04-29 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $56.33 | 3,500 | $197,155 | 43,880 | -7.4% |
| 2013-03-26 20:03 | 2013-03-26 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $56.00 | 5,000 | $280,000 | 47,380 | -9.5% |
| 2013-02-05 00:27 | 2013-02-01 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | OPT+S | $54.28 | 5,000 | $271,400 | 52,380 | -8.7% |
| 2012-11-07 23:24 | 2012-10-24 | LLY | ELI LILLY & Co | Mahony Susan | Officer; SVP & Pres., Lilly Oncology | Pharmaceutical Preparations | SALE | $50.45 | 10,000 | $504,500 | 20,620 | -32.7% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.